Professor Richard Lock was recruited as Head of Children’s Cancer Institute’s Leukaemia Biology Program in 1998 from the position of Associate Professor, Department of Medicine and Department of Biochemistry and Molecular Biology, University of Louisville, Kentucky, USA. Prior to his move, he had attained an international reputation in the cancer-related fields of cell cycle control, drug resistance and mechanisms of programmed cell death (apoptosis).
At Children’s Cancer Institute, Professor Lock has successfully developed a clinically relevant laboratory model for the in vivo growth of human acute lymphoblastic leukaemia cells – the first such model in Australia. The model now plays a central role in the preclinical evaluation of anticancer agents and the identification of new targets for targeted therapies as part of the US National Cancer Institute's Pediatric Preclinical Testing Consortium.
Professor Lock's contribution to cancer research has been reflected in his authorship of more than 155 peer-reviewed papers, including several in prestigious journals such as Blood, Cancer Research, Cell Stem Cell, Clinical Cancer Research, The Journal of Biological Chemistry, Molecular and Cellular Biology, and Oncogene. He is currently a National Health and Medical Research Council Senior Research Fellow, and has been awarded research grants by the National Cancer Institute (USA), Cancer Council NSW, and the National Health and Medical Research Council (NHMRC).
Professor Lock is the inaugural Deputy Director of the UNSW Centre for Childhood Cancer Research. He is also Head, Preclinical Drug Testing Core (PDTC) Team for the Zero Childhood Cancer personalised medicine program led by Children's Cancer Institute and Sydney Children's Hospitals Network.